OTC - ACTIVE INGREDIENT SECTION
Active Ingredient
Salicylic Acid 2%
Active Ingredient
Salicylic Acid 2%
Purpose:
psoriasis and seborrheic dermatitis
Keep out of reach of children. If swallowed, get immediate medical help or contact a Poison Control Center immediately.
Uses relieves and helps prevent recurrence of skin itching, irritation, redness, flaking, scaling due to psoriasis and seborrheic dermatitis
Warnings
Directions
Apply to affected area one to four times daily or as directed by a doctor
Inactive Ingredients
Alpha-Tocopherol Acetate, Bidens Tripartita Flower Top, Calcium Stearate, Cod Liver Oil, Eucalyptus Oil, Honey, Lavender Oil, Lysozyme Hydrochloride, Matricaria Recutita, Mineral Oil, Petrolatum, Retinol.| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 54427-001-01 | 2019-11-27 | C162847 | 48780-1 | 9855d018-eaef-cd31-e053-dbdaa90ab51a | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 54427-001-01 | BIOARPIL | 1 in 1 BOX | OINTMENT | 1 | 4 | |
| 54427-001-01 | BIOARPIL | 140 g in 1 JAR | OINTMENT | 140 | 4 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| SALICYLIC ACID | ACTIVE INGREDIENT | O414PZ4LPZ | 4 | |
| SALICYLIC ACID | ACTIVE MOIETY | O414PZ4LPZ | 4 | |
| .ALPHA.-TOCOPHEROL ACETATE | INACTIVE INGREDIENT | 9E8X80D2L0 | 4 | |
| BIDENS TRIPARTITA FLOWERING TOP | INACTIVE INGREDIENT | 7378E9Z0AL | 4 | |
| CALCIUM STEARATE | INACTIVE INGREDIENT | 776XM7047L | 4 | |
| COD LIVER OIL | INACTIVE INGREDIENT | BBL281NWFG | 4 | |
| EUCALYPTUS OIL | INACTIVE INGREDIENT | 2R04ONI662 | 4 | |
| HONEY | INACTIVE INGREDIENT | Y9H1V576FH | 4 | |
| LAVENDER OIL | INACTIVE INGREDIENT | ZBP1YXW0H8 | 4 | |
| LYSOZYME HYDROCHLORIDE | INACTIVE INGREDIENT | 4YRW73H69V | 4 | |
| MATRICARIA RECUTITA | INACTIVE INGREDIENT | G0R4UBI2ZZ | 4 | |
| MINERAL OIL | INACTIVE INGREDIENT | T5L8T28FGP | 4 | |
| PETROLATUM | INACTIVE INGREDIENT | 4T6H12BN9U | 4 | |
| RETINOL | INACTIVE INGREDIENT | G2SH0XKK91 | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 54427-001 | 54427-001-01 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| SALICYLIC ACID | O414PZ4LPZ | ACTIB |
| .ALPHA.-TOCOPHEROL ACETATE | 9E8X80D2L0 | IACT |
| BIDENS TRIPARTITA FLOWERING TOP | 7378E9Z0AL | IACT |
| CALCIUM STEARATE | 776XM7047L | IACT |
| COD LIVER OIL | BBL281NWFG | IACT |
| EUCALYPTUS OIL | 2R04ONI662 | IACT |
| HONEY | Y9H1V576FH | IACT |
| LAVENDER OIL | ZBP1YXW0H8 | IACT |
| LYSOZYME HYDROCHLORIDE | 4YRW73H69V | IACT |
| MATRICARIA RECUTITA | G0R4UBI2ZZ | IACT |
| MINERAL OIL | T5L8T28FGP | IACT |
| PETROLATUM | 4T6H12BN9U | IACT |
| RETINOL | G2SH0XKK91 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, EXTENDED RELEASE / ORAL | NA | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | TABLET / ORAL | 3.5 mg | ||
| LAVENDER OIL | LAVENDER OIL | ZBP1YXW0H8 | GEL / TOPICAL | 0.1 %w/w | ||
| CALCIUM STEARATE | CALCIUM STEARATE | 776XM7047L | TABLET, COATED / ORAL | 12.2 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OINTMENT / OPHTHALMIC | 59.5 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, DELAYED RELEASE / ORAL | 5.67 mg | ||
| CALCIUM STEARATE | CALCIUM STEARATE | 776XM7047L | TABLET, ORALLY DISINTEGRATING / ORAL | 112 mg | ||
| LAVENDER OIL | LAVENDER OIL | ZBP1YXW0H8 | INHALANT / NASAL | NA | ||
| CALCIUM STEARATE | CALCIUM STEARATE | 776XM7047L | TABLET / BUCCAL | 1.42 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUSPENSION / OPHTHALMIC | 0.1 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OINTMENT / TOPICAL | 9938 mg | ||
| CALCIUM STEARATE | CALCIUM STEARATE | 776XM7047L | CAPSULE / ORAL | 21.1 mg | ||
| CALCIUM STEARATE | CALCIUM STEARATE | 776XM7047L | TABLET / SUBLINGUAL | 2 mg | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | OINTMENT / TOPICAL | 7275 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | SOAP / TOPICAL | 0.85 %w/w | ||
| CALCIUM STEARATE | CALCIUM STEARATE | 776XM7047L | TABLET, DELAYED RELEASE / ORAL | 29 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUSPENSION / TOPICAL | 82 %w/w | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | OINTMENT / OPHTHALMIC | 88.4 %w/w | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | EMULSION / TOPICAL | 7.8 %w/w | ||
| .ALPHA.-TOCOPHEROL ACETATE | .ALPHA.-TOCOPHEROL ACETATE | 9E8X80D2L0 | CAPSULE / ORAL | 2 mg | ||
| EUCALYPTUS OIL | EUCALYPTUS OIL | 2R04ONI662 | SYRUP / ORAL | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | PASTE / TOPICAL | 47.5 %w/w | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | OINTMENT / VAGINAL | 4084 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, COATED / ORAL | 1.5 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | FILM / TRANSDERMAL | 11.42 mg | ||
| .ALPHA.-TOCOPHEROL ACETATE | .ALPHA.-TOCOPHEROL ACETATE | 9E8X80D2L0 | TABLET / ORAL | 0.5 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | LOTION / TOPICAL | 1428 mg | ||
| CALCIUM STEARATE | CALCIUM STEARATE | 776XM7047L | POWDER / ORAL | 600 mg | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | CREAM / TOPICAL | 4213 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SYSTEM / TOPICAL | 654.36 mg | ||
| CALCIUM STEARATE | CALCIUM STEARATE | 776XM7047L | CAPSULE, EXTENDED RELEASE / ORAL | 91.9 mg | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | CAPSULE, EXTENDED RELEASE / ORAL | 0.07 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OIL / TOPICAL | 43.29 %v/v | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | OINTMENT / AURICULAR (OTIC) | NA | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | OINTMENT, AUGMENTED / TOPICAL | 81.94 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | GEL / TOPICAL | 2.5 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SYSTEM / TRANSDERMAL | 6.09 mg | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | LOTION / TOPICAL | 25 %w/w | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | TABLET, EXTENDED RELEASE / ORAL | 0.18 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET / ORAL | 113.75 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUSPENSION / AURICULAR (OTIC) | 0.5 %w/v | ||
| .ALPHA.-TOCOPHEROL ACETATE | .ALPHA.-TOCOPHEROL ACETATE | 9E8X80D2L0 | FILM / BUCCAL | 0.09 mg | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | CREAM, AUGMENTED / TOPICAL | 26 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | FILM, EXTENDED RELEASE / TRANSDERMAL | 34 mg | ||
| CALCIUM STEARATE | CALCIUM STEARATE | 776XM7047L | TABLET, CHEWABLE / ORAL | 240 mg | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | LIQUID / RESPIRATORY (INHALATION) | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | TABLET, FILM COATED / ORAL | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SUPPOSITORY / VAGINAL | 30 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SPRAY / TOPICAL | 1379 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | SOAP / TOPICAL | 0.82 %w/w | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | CAPSULE / VAGINAL | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | CAPSULE / ORAL | 120 mg | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | CREAM / TOPICAL | 2772 mg | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | SUPPOSITORY / VAGINAL | 27 mg | ||
| CALCIUM STEARATE | CALCIUM STEARATE | 776XM7047L | TABLET / ORAL | 280 mg | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | AEROSOL, FOAM / TOPICAL | 7.9 %w/w | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | DROPS / ORAL | NA | ||
| MINERAL OIL | MINERAL OIL | T5L8T28FGP | OINTMENT / AURICULAR (OTIC) | NA | ||
| PETROLATUM | PETROLATUM | 4T6H12BN9U | SPONGE / TOPICAL | NA |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 5c12489e-f8df-4704-9d67-72b4277d1efe | e700b28f-268a-4384-a9bb-a83c42b41313 | 2012-12-18 | Warnings | 5c12489e-f8df-4704-9d67-72b4277d1efe e700b28f-268a-4384-a9bb-a83c42b41313 |
Adverse event summaries are temporarily unavailable. Other product information remains available.